Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421761 | 0.93 | PGR (0.39) | MAPK14EIF4A3PTGDR2RIPK1TP53 | |
| SCHEMBL424682 | 0.90 | PTGDR2 (0.38) | MAPK14EIF4A3PTGDR2TP53MAPT | |
| SCHEMBL422736 | 0.90 | MAPK14 (0.41) | MAPK14RIPK1TP53MAPTHCRTR1 | |
| SCHEMBL421766 | 0.87 | MAPK14 (0.39) | MAPK14PTGDR2KCNK3PGR | |
| SCHEMBL422505 | 0.86 | MAPK14 (0.41) | MAPK14CSNK1EPGR | |
| SCHEMBL424281 | 0.84 | MAPK14 (0.42) | MAPK14RIPK1BRD4PGR | |
| SCHEMBL12942148 | 0.83 | KCNK3 (0.36) | METAP2PTGDR2KCNK3HCRTR1HCRTR2 | |
| SCHEMBL423833 | 0.82 | MAPK14 (0.37) | MAPK14RIPK1HSD17B3HCRTR1HCRTR2 | |
| SCHEMBL424176 | 0.82 | MAPK14 (0.37) | MAPK14RIPK1HSD17B3HCRTR1HCRTR2 | |
| SCHEMBL10109877 | 0.81 | MAPK14 (0.39) | MAPK14TP53MAPTSLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546438-B2 | Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546438-B2 | Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546438-B2 | Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| EP-2376482-B1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO KG (DE) | 2013-03-06 | — | — | EP | disclosed |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| WO-2010075962-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | TPMT, MAVS, EIF2AK2 | MAPK14 2294/4885EIF4A3 491/4885METAP2 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.